Regen Biopharma signs non-binding LOI to acquire 95% of Canary Oncoceutics for $1M cash and stock

Regen BioPharma Inc

Consideration: $1,000,000 cash plus common shares valued at RGBP's average share price pre-closing.
Closing contingent on raising $50,000,000 solely for Canary diagnostics and product development.
Milestone payments up to $10,000,000 per test product, including $3M upon FDA approval.
Earned royalty on net sales: 2.5% up to $250M, 4% up to $500M, 5% above $500M.
IP licensed from Cornell University enables patient-derived tumor vascular nets for drug testing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.